ZIOPHARM ONCOLOGY INC - COM (TCRT) Institutional Ownership

13F Institutional Holders and Ownership History from Q1 2014 to Q1 2024

Type / Class
Equity / COM
Symbol
TCRT on Nasdaq
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Institutional Holders of ZIOPHARM ONCOLOGY INC - COM (TCRT) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2024 Q1 0 $0 -$2,879,727 0
2023 Q4 40,789,087 $2,884,403 -$1,166,504 $0.07 78
2023 Q3 55,617,707 $7,329,471 -$4,077,724 $0.13 86
2023 Q2 67,127,079 $34,227,370 -$2,159,131 $0.51 98
2023 Q1 70,909,094 $44,669,856 -$6,711,720 $0.63 106
2022 Q4 77,760,476 $52,789,242 +$1,721,467 $0.65 117
2022 Q3 74,617,512 $128,418,768 +$4,263,503 $1.72 117
2022 Q2 73,167,927 $90,726,991 -$25,689,277 $1.24 114
2022 Q1 100,410,416 $65,716,457 -$29,271,843 $0.65 134
2021 Q4 142,928,596 $155,860,863 +$39,717,323 $1.09 155
2021 Q3 106,498,737 $193,856,679 -$20,125,101 $1.82 156
2021 Q2 112,726,359 $297,591,838 -$13,555,714 $2.64 149
2021 Q1 117,429,004 $422,706,255 +$23,265,814 $3.60 147
2020 Q4 111,617,223 $281,282,676 +$9,533,340 $2.52 147
2020 Q3 107,687,634 $271,528,606 +$10,900,602 $2.52 150
2020 Q2 102,893,652 $337,471,159 +$16,684,872 $3.28 140
2020 Q1 98,933,201 $242,829,123 +$30,615,666 $2.45 139
2019 Q4 85,461,580 $403,354,480 +$12,829,574 $4.72 144
2019 Q3 82,642,681 $353,705,540 +$50,900,441 $4.28 139
2019 Q2 70,281,800 $409,743,457 +$49,253,962 $5.83 137
2019 Q1 62,544,537 $240,802,681 +$14,464,745 $3.85 120
2018 Q4 61,699,827 $114,661,170 +$5,124,874 $1.87 130
2018 Q3 57,378,724 $183,606,590 +$3,554,517 $3.20 124
2018 Q2 56,262,369 $169,915,659 -$5,486,208 $3.02 124
2018 Q1 58,352,115 $228,944,869 +$3,850,914 $3.92 130
2017 Q4 57,255,104 $237,036,323 -$4,356,453 $4.14 126
2017 Q3 57,992,531 $356,064,019 -$15,703,461 $6.14 119
2017 Q2 60,430,502 $375,845,193 +$44,522,781 $6.22 120
2017 Q1 53,234,743 $337,236,246 +$41,748,087 $6.34 122
2016 Q4 53,986,736 $288,859,735 +$7,883,237 $5.35 134
2016 Q3 54,855,759 $308,587,668 -$27,174,782 $5.63 139
2016 Q2 59,750,917 $328,063,632 +$17,690,732 $5.49 152
2016 Q1 56,052,054 $415,869,934 -$40,228,997 $7.42 141
2015 Q4 60,982,687 $506,743,448 -$20,562,378 $8.31 154
2015 Q3 63,276,927 $570,116,840 -$35,150,166 $9.01 137
2015 Q2 65,962,294 $791,520,860 -$25,789,753 $12.00 152
2015 Q1 68,488,155 $736,509,986 +$262,414,817 $10.77 125
2014 Q4 45,918,808 $232,790,574 +$2,171,025 $5.07 84
2014 Q3 47,889,131 $126,256,822 -$7,047,125 $2.64 92
2014 Q2 50,839,715 $203,989,176 -$22,000,604 $4.03 91
2014 Q1 56,102,138 $255,479,862 +$1,468,778 $4.58 94